Advances in single-cell technologies have enabled high-resolution dissection of tissue composition. Several tools for dimensionality reduction are available to analyze the large number of parameters generated in single-cell studies. Recently, a nonlinear dimensionality-reduction technique, uniform […]
Click here to learn more about this conference.
Summary of Meeting:The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. […]
Click here to learn more about this presentation.
ESMO Asia 2018 will keep oncology professionals in the Asia-Paciﬁc region up to date with the fast pace of oncology science and education, and provide important networking opportunities with international peers. More.
As a benefit for attending the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) provides enduring materials free of charge for the specific programs attended. If you are a SITC member, or member of […]
The 4th annual NeoAg Summit is returning to Boston this November to provide your team with one all-inclusive forum to successfully target tumor-specific neoantigens and bring to market personalized cancer vaccines and cellular therapies. More.
A multi-professional platform for oncology education and exchange, and for immense international visibility for scientific research, this year the Congress featured a dedicated nursing track through a collaboration with the European Oncology Nursing Society (EONS). […]
Oxford Global’s R&D US Series features 3 outstanding programmes: our long-running 5th Annual Drug Discovery and Chemistry USA Congress, the 3rd Annual Biomarkers & Precision Medicine USA Congress, and fast-emerging Advances in Immuno-Oncology USA Congress. More.
Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving to be effective at restoring T cell-mediated immune responses that can lead to marked and sustained clinical responses, but only in some patients and […]
The future of immuno-oncology drug development is positioned in combination therapies, where immunotherapy modalities are tested in rational combinations with other immunotherapies or targeted therapies for synergistic effects. Combination immunotherapy promises to deliver long-term survival […]